Published in Eur J Endocrinol on July 06, 2009
Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone (2010) 1.39
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet (2013) 0.96
Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. Calcif Tissue Int (2011) 0.80
A de novo mosaic mutation of PHEX in a boy with hypophosphatemic rickets. J Hum Genet (2015) 0.75
Treatment of Hypophosphatemic Rickets with Phosphate and Active Vitamin D in Japan: A Questionnaire-based Survey. Clin Pediatr Endocrinol (2013) 0.75
Bilateral pseudarthrosis of the femoral neck in a 25-year-old male with hereditary hypophosphatemic rickets. Case Rep Orthop (2014) 0.75
Familial hypophosphatemia: an unusual presentation with low back ache, heel pain, and a limp in a young man, and literature review. Clin Rheumatol (2010) 0.75
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature (2002) 5.62
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 3.03
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med (2011) 2.68
Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med (2005) 2.59
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg (2012) 2.39
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int (2005) 2.26
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med (2008) 2.25
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial (2013) 2.07
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med (2002) 2.00
Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol (2008) 1.99
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (2007) 1.93
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet (2002) 1.89
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A (2009) 1.80
Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int (2005) 1.78
Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. Nephrol Dial Transplant (2009) 1.76
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation (2012) 1.75
Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (2010) 1.74
Green tea inhibits human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha activation. Mol Pharmacol (2004) 1.74
Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension (2002) 1.73
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol (2011) 1.68
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res (2012) 1.61
TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J Biochem (2011) 1.61
IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3- cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A (2006) 1.61
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol (2003) 1.60
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant (2008) 1.56
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension (2006) 1.55
Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab (2004) 1.55
Isolation and potential existence of side population cells in adult human kidney. Int J Urol (2008) 1.55
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol (2014) 1.55
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab (2004) 1.54
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol (2004) 1.52
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int (2008) 1.52
Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. Circ J (2009) 1.52
Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol (2006) 1.51
Marked hypercalcemia in a patient with hypocalciuric hypercalcemia without a mutation in the calcium-sensing receptor gene. Intern Med (2002) 1.50
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens (2008) 1.49
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (2009) 1.47
Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract (2005) 1.46
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int (2010) 1.46
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem (2006) 1.46
Interstitial deletion of 13q14.13-q32.3 presenting with Arima syndrome and bilateral retinoblastoma. Brain Dev (2010) 1.45
Ghrelin directly regulates bone formation. J Bone Miner Res (2004) 1.44
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res (2002) 1.44
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension (2007) 1.43
Hepatoblastoma in a patient with sotos syndrome. J Pediatr (2009) 1.40
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension (2003) 1.40
In vitro study of patient's and physician's radiation exposure in the performance of epiduroscopy. Reg Anesth Pain Med (2008) 1.39
Congenital infection-like syndrome with intracranial calcification. Brain Dev (2010) 1.39